SCHEMBL4068111

SCHEMBL4068111

CC(=O)c1ncnc2c1ccn2S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
HTT P42858 2/20 0.39
POLB P06746 1/20 0.39
ALDH3A1 P30838 1/20 0.39
NOD1 Q9Y239 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
BRD4 O60885 1/20 0.37
PKM P14618 2/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
HTR6 P50406 1/20 0.36
VEGFA P15692 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
GBA1 P04062 1/20 0.36
RAB9A P51151 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3556162 0.90 L3MBTL1 (0.49) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL15428434 0.89 L3MBTL1 (0.48) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL4119927 0.85 L3MBTL1 (0.45) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL13960904 0.85 L3MBTL1 (0.45) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL13769391 0.84 L3MBTL1 (0.46) L3MBTL1NOD1ALDH1A1RAPGEF4CA1
SCHEMBL260617 0.82 L3MBTL1 (0.55) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL4067920 0.82 L3MBTL1 (0.44) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL4075074 0.80 L3MBTL1 (0.52) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL30752005 0.80 L3MBTL1 (0.52) L3MBTL1HTTPOLBALDH3A1NOD1
SCHEMBL14427677 0.80 L3MBTL1 (0.52) L3MBTL1HTTPOLBALDH3A1NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-23 US disclosed
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-23 US disclosed
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-23 US disclosed
US-20140171454-A1 Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 US disclosed
US-20140171454-A1 Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 US disclosed
US-20140171454-A1 Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 US disclosed
US-8741912-B2 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-03 US disclosed
US-8741912-B2 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-03 US disclosed
US-8741912-B2 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-03 US disclosed
US-8633205-B2 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
EP-1844050-B1 PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMA (US) 2009-01-14 EP disclosed
EP-2001884-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES Vertex Pharmaceuticals, Inc. (US) 2008-12-17 EP disclosed
WO-2007117494-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-18 WO disclosed
WO-2007117494-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-18 WO disclosed
EP-1844050-A1 PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE Vertex Pharmaceuticals, Inc. (US) 2007-10-17 EP disclosed
US-20070004762-A9 Pyrrolopyrimidines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-01-04 US disclosed
US-20070004762-A9 Pyrrolopyrimidines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-01-04 US disclosed
US-20070004762-A9 Pyrrolopyrimidines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-01-04 US disclosed
WO-2006096270-A1 PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-09-14 WO disclosed
US-20060183761-A1 Pyrrolopyrimidines useful as inhibitors of protein kinase LEDEBOER MARK 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004762-A9 Pyrrolopyrimidines useful as inhibitors of protein kinase PRKDC, MAP3K20, MAP3K5 L3MBTL1 2911/4885HTT 1297/4885POLB 789/4885
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 L3MBTL1 2062/4885HTT 3012/4885POLB 1175/4885
US-20140171454-A1 Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases PRKDC, DCK, CDK2 L3MBTL1 2823/4885HTT 2155/4885POLB 755/4885
US-20060183761-A1 Pyrrolopyrimidines useful as inhibitors of protein kinase PRKDC, MAP3K20, MAP3K5 L3MBTL1 2911/4885HTT 1297/4885POLB 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.